^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CD19x22 CAR T
i
Other names: CD19x22 CAR T
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
University of Colorado
Drug class:
CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
Related drugs:
2ms
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL (clinicaltrials.gov)
P1, N=26, Recruiting, University of Colorado, Denver | Not yet recruiting --> Recruiting
Enrollment open • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD19x22 CAR T
3ms
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL (clinicaltrials.gov)
P1, N=26, Not yet recruiting, University of Colorado, Denver
New P1 trial • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD19x22 CAR T
over1year
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients (clinicaltrials.gov)
P1, N=20, Recruiting, University of Colorado, Denver | Active, not recruiting --> Recruiting
Enrollment open • CAR T-Cell Therapy
|
CD19x22 CAR T
2years
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients (clinicaltrials.gov)
P1, N=3, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting | N=20 --> 3
Enrollment closed • Enrollment change • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19x22 CAR T
Share via
